Inovio, Regeneron Plan Clinical Trial of Triple-Combo Immunotherapy for Brain Tumors – Immuno-Oncology News
Immuno-Oncology News |
Inovio, Regeneron Plan Clinical Trial of Triple-Combo Immunotherapy for Brain Tumors
Immuno-Oncology News Patients with a newly diagnosed glioblastoma multiforme (GBM) brain tumor will be able to enroll soon in a Phase 1b/2a clinical trial of a triple-combination immunotherapy for the cancer. Inovio Pharmaceuticals will conduct the study to evaluate its T … Regeneron and Inovio to aim immunotherapy at hard-to-treat brain tumour Inovio (INO) Q1 Loss Narrower Than Expected, Revenues Beat Inovio Pharmaceuticals Reports 2017 First Quarter Financial Results |
